Q-omics provides the consensus-scored C14orf39 profile across patient tissues and cancer cell-line models. C14orf39 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, C14orf39 is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, C14orf39 RNA expression shows 14,299 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, STAD, and THYM as cancer lineages where C14orf39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C14orf39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C14orf39 survival associations across molecular data types. C14orf39 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C14orf39 RNA expression–survival associations across cancer types. High C14orf39 expression shows unfavorable associations in KIRP, UCEC, ACC and SCLC, but favorable associations in CESC and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for C14orf39 RNA expression.
This table summarizes C14orf39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C14orf39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C14orf39 shows lower tumor expression in STAD, THCA, HNSC, READ and COAD and higher tumor expression in LUAD. The STAD box plot shows higher C14orf39 RNA expression in normal versus tumor tissue (log2 FC = −0.408, t-test p = .001).
This table shows molecular features associated with C14orf39 in patient tissues and cancer cell lines. In patient samples, C14orf39 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C14orf39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
